| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
|
Lancet
|
2016
|
3.02
|
|
2
|
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
|
Am Heart J
|
2015
|
0.77
|
|
3
|
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014.
|
Int J Cardiol
|
2014
|
0.75
|
|
4
|
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
|
Kidney Int
|
2016
|
0.75
|
|
5
|
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease.
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
6
|
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome.
|
Am Heart J
|
2017
|
0.75
|
|
7
|
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.
|
J Am Coll Cardiol
|
2017
|
0.75
|